CRISPR Therapeutics AG (CRSP) Total Current Liabilities (2015 - 2026)

CRISPR Therapeutics AG has disclosed Total Current Liabilities across 12 years of filings, most recently posting $136.3 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $136.3 million, up 14.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $136.3 million (up 14.1% YoY), and the FY2025 annual result was $149.1 million, up 69.88% from the prior year.
• Total Current Liabilities came in at $136.3 million for Q1 2026 at CRISPR Therapeutics AG, down from $149.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $150.9 million in Q3 2022 to a low of $87.8 million in Q4 2024.
• The 5-year median for Total Current Liabilities is $119.4 million (2025), against an average of $121.1 million.
• Across the five-year window, Total Current Liabilities slipped 26.27% in 2023 and jumped 69.88% in 2025, its largest moves.
• CRISPR Therapeutics AG's Total Current Liabilities stood at $121.1 million in 2022, then dropped by 10.17% to $108.8 million in 2023, then retreated by 19.31% to $87.8 million in 2024, then surged by 69.88% to $149.1 million in 2025, then fell by 8.61% to $136.3 million in 2026.
• The last three Total Current Liabilities figures came in at $136.3 million (Q1 2026), $149.1 million (Q4 2025), and $119.0 million (Q3 2025), per Business Quant data.